2025 Q2 -tulosraportti
198 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 800 | - | - | ||
| 18 867 | - | - | ||
| 3 000 | - | - | ||
| 5 963 | - | - | ||
| 1 021 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sitten · MuokattuOdds? Under 5 what do you mean? Short-term drop or permanent fall below? Probably one of the safest bio stocks if one thinks long-term. Reason: Technology stock that will realize value based on technology and not on the results of clinical studies. Zero debt. The CEO has stated this was the last emission. He expects an agreement with cash inflow. The entire management has bought shares. They wouldn't do that if they thought they would be diluted. Ironclad control over expenses. Countless opportunities. Technology validated in several studies with the same result. Positioned in the world's hottest biomarked in vivo cell therapy CAR-T and gene therapy. Texas university on behalf of defense and state in USA will investigate vaccine potential and cover all costs. They will prevent pandemics and bio-attacks. Agreement with one of pharma's big 5. The price can fluctuate under 5 but can go to 60-80 or more upon acquisition. One of the best risk / reward cases in the bio industry. The bio industry worldwide is aware of the technology's potential. Little known here in Scandinavia. Nice that it's ordinary people who have positioned themselves and not celebrities. Those who get rich here stay long. Others can earn well and that's not wrong either. The CEO has become an international authority with respect in the field. Biomedia worldwide have more and more coverage. No one can know where the stock market will swing, and there are starting to be many different actors active in the stock. One must make one's own assessments based on one's own premises.
3 t sitten3 t sittenWhat are the odds that the price will drop below 5?·2 t sitten · MuokattuOdds? Under 5, what do you mean? Short-term drop or a lasting fall below? Probably one of the safest bio stocks if one thinks long-term. Reason: A technology stock that will realize value from technology and not from clinical study results. Zero debt; the CEO has stated this was the last share issue. He expects a deal with cash inflow. The entire management has bought shares. They wouldn't do that if they thought they would be diluted. Ironclad control over expenses. Countless opportunities. Technology validated in several studies with the same result. Positioned in the world's hottest biomarket in vivo cell therapy CAR-T and gene therapy. Texas university on behalf of defense and state will investigate vaccine potential and covers all costs. Agreement with one of pharma's big 5. The price can fluctuate under 5 but can go to 60-80 or more upon acquisition. One of the best risk / reward cases in the bio industry. The world is aware of the technology's potential. Those who get rich here sit long. Others can earn well, and that's not wrong either. The CEO has become an international authority with respect in the field. No one can know where the stock market swings, and there are starting to be many different actors active in the stock. One must make their own assessments based on their own premises.
3 t sitten3 t sittenHidden stock, very little conversations found on socials and forums. Was surprised that finlands biggest stock forum Inderes had 0 posts about crna in their otherwise very active forum
·4 t sitten · MuokattuEnjoy the weekend folks, if this goes up to 8 by next week I'll invite to a pre-party in early April 🫡 then we'll have a CRNA gathering at my place in Oslo and enjoy a Friday after work 🫶🏻
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
198 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sitten · MuokattuOdds? Under 5 what do you mean? Short-term drop or permanent fall below? Probably one of the safest bio stocks if one thinks long-term. Reason: Technology stock that will realize value based on technology and not on the results of clinical studies. Zero debt. The CEO has stated this was the last emission. He expects an agreement with cash inflow. The entire management has bought shares. They wouldn't do that if they thought they would be diluted. Ironclad control over expenses. Countless opportunities. Technology validated in several studies with the same result. Positioned in the world's hottest biomarked in vivo cell therapy CAR-T and gene therapy. Texas university on behalf of defense and state in USA will investigate vaccine potential and cover all costs. They will prevent pandemics and bio-attacks. Agreement with one of pharma's big 5. The price can fluctuate under 5 but can go to 60-80 or more upon acquisition. One of the best risk / reward cases in the bio industry. The bio industry worldwide is aware of the technology's potential. Little known here in Scandinavia. Nice that it's ordinary people who have positioned themselves and not celebrities. Those who get rich here stay long. Others can earn well and that's not wrong either. The CEO has become an international authority with respect in the field. Biomedia worldwide have more and more coverage. No one can know where the stock market will swing, and there are starting to be many different actors active in the stock. One must make one's own assessments based on one's own premises.
- 3 t sitten3 t sittenWhat are the odds that the price will drop below 5?·2 t sitten · MuokattuOdds? Under 5, what do you mean? Short-term drop or a lasting fall below? Probably one of the safest bio stocks if one thinks long-term. Reason: A technology stock that will realize value from technology and not from clinical study results. Zero debt; the CEO has stated this was the last share issue. He expects a deal with cash inflow. The entire management has bought shares. They wouldn't do that if they thought they would be diluted. Ironclad control over expenses. Countless opportunities. Technology validated in several studies with the same result. Positioned in the world's hottest biomarket in vivo cell therapy CAR-T and gene therapy. Texas university on behalf of defense and state will investigate vaccine potential and covers all costs. Agreement with one of pharma's big 5. The price can fluctuate under 5 but can go to 60-80 or more upon acquisition. One of the best risk / reward cases in the bio industry. The world is aware of the technology's potential. Those who get rich here sit long. Others can earn well, and that's not wrong either. The CEO has become an international authority with respect in the field. No one can know where the stock market swings, and there are starting to be many different actors active in the stock. One must make their own assessments based on their own premises.
- 3 t sitten3 t sittenHidden stock, very little conversations found on socials and forums. Was surprised that finlands biggest stock forum Inderes had 0 posts about crna in their otherwise very active forum
- ·4 t sitten · MuokattuEnjoy the weekend folks, if this goes up to 8 by next week I'll invite to a pre-party in early April 🫡 then we'll have a CRNA gathering at my place in Oslo and enjoy a Friday after work 🫶🏻
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 800 | - | - | ||
| 18 867 | - | - | ||
| 3 000 | - | - | ||
| 5 963 | - | - | ||
| 1 021 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
198 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sitten · MuokattuOdds? Under 5 what do you mean? Short-term drop or permanent fall below? Probably one of the safest bio stocks if one thinks long-term. Reason: Technology stock that will realize value based on technology and not on the results of clinical studies. Zero debt. The CEO has stated this was the last emission. He expects an agreement with cash inflow. The entire management has bought shares. They wouldn't do that if they thought they would be diluted. Ironclad control over expenses. Countless opportunities. Technology validated in several studies with the same result. Positioned in the world's hottest biomarked in vivo cell therapy CAR-T and gene therapy. Texas university on behalf of defense and state in USA will investigate vaccine potential and cover all costs. They will prevent pandemics and bio-attacks. Agreement with one of pharma's big 5. The price can fluctuate under 5 but can go to 60-80 or more upon acquisition. One of the best risk / reward cases in the bio industry. The bio industry worldwide is aware of the technology's potential. Little known here in Scandinavia. Nice that it's ordinary people who have positioned themselves and not celebrities. Those who get rich here stay long. Others can earn well and that's not wrong either. The CEO has become an international authority with respect in the field. Biomedia worldwide have more and more coverage. No one can know where the stock market will swing, and there are starting to be many different actors active in the stock. One must make one's own assessments based on one's own premises.
- 3 t sitten3 t sittenWhat are the odds that the price will drop below 5?·2 t sitten · MuokattuOdds? Under 5, what do you mean? Short-term drop or a lasting fall below? Probably one of the safest bio stocks if one thinks long-term. Reason: A technology stock that will realize value from technology and not from clinical study results. Zero debt; the CEO has stated this was the last share issue. He expects a deal with cash inflow. The entire management has bought shares. They wouldn't do that if they thought they would be diluted. Ironclad control over expenses. Countless opportunities. Technology validated in several studies with the same result. Positioned in the world's hottest biomarket in vivo cell therapy CAR-T and gene therapy. Texas university on behalf of defense and state will investigate vaccine potential and covers all costs. Agreement with one of pharma's big 5. The price can fluctuate under 5 but can go to 60-80 or more upon acquisition. One of the best risk / reward cases in the bio industry. The world is aware of the technology's potential. Those who get rich here sit long. Others can earn well, and that's not wrong either. The CEO has become an international authority with respect in the field. No one can know where the stock market swings, and there are starting to be many different actors active in the stock. One must make their own assessments based on their own premises.
- 3 t sitten3 t sittenHidden stock, very little conversations found on socials and forums. Was surprised that finlands biggest stock forum Inderes had 0 posts about crna in their otherwise very active forum
- ·4 t sitten · MuokattuEnjoy the weekend folks, if this goes up to 8 by next week I'll invite to a pre-party in early April 🫡 then we'll have a CRNA gathering at my place in Oslo and enjoy a Friday after work 🫶🏻
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 800 | - | - | ||
| 18 867 | - | - | ||
| 3 000 | - | - | ||
| 5 963 | - | - | ||
| 1 021 | - | - |
Välittäjätilasto
Dataa ei löytynyt